Are We Closer to a Cure With Perioperative Immunotherapy in Resectable NSCLC? Latest Evidence, Current Conclusions, and Ongoing Questions in Clinical Care
PeerView
166 views
26 slides
Oct 18, 2024
Slide 1 of 26
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
About This Presentation
Chair Prof. Solange Peters, MD, PhD, discusses NSCLC in this CME activity titled “Are We Closer to a Cure With Perioperative Immunotherapy in Resectable NSCLC? Latest Evidence, Current Conclusions, and Ongoing Questions in Clinical Care.” For the full presentation, downloadable Practice Aids, an...
Slide Content
Are We Closer to a Cure With Perioperative
Immunotherapy in Resectable NSCLC?
Latest Evidence, Current Conclusions, and
Ongoing Questions in Clinical Care
Prof. Solange Peters, MD, PhD
Chair and Professor, Medical Oncology
Full Professor
University Hospital of Lausanne
| Lausanne, Switzerland
Go online to access full CME information, including faculty disclosures.
Copyright © 2000-2024, PeerView
Immunotherapy in Resectable NSCLC?
Latest Evidence, Current Conclusions, and
Ongoing Questions in Clinical Care
Prof. Solange Peters, MD, PhD
Chair and Professor, Medical Oncology
Full Professor
University Hospital of Lausanne
| Lausanne, Switzerland
Go online to access full CME information, including faculty disclosures.
Copyright © 2000-2024, PeerView
Our Goals for Today
Augment your knowledge of the latest data on
immunotherapy in resectable NSCLC
Improve your ability to interpret clinical evidence supporting
the use of different immunotherapy approaches to personalise
the management of resectable NSCLC.
Equip you with skills for devising individualised care plans
inclusive of immunotherapy to optimise outcomes for patients
with resectable NSCLC.
Copyright © 2000-2024, PeerView
Augment your knowledge of the latest data on
immunotherapy in resectable NSCLC
Improve your ability to interpret clinical evidence supporting
the use of different immunotherapy approaches to personalise
the management of resectable NSCLC.
Equip you with skills for devising individualised care plans
inclusive of immunotherapy to optimise outcomes for patients
with resectable NSCLC.
Copyright © 2000-2024, PeerView
IMMUNOTHERAPY IN RESECTABLE NSCLC | OUTLINE
PART 1
PART 2
Shining a Light on the Clinical Data
Supporting the Use of Adjuvant,
Neoadjuvant, and Perioperative
Immunotherapy in Resectable NSCLC
PeerView.com/AWU827
Closer to a Cure or Added Clinical
Complexity? Making Sense of the
Innovations for Immunotherapy in
Resectable NSCLC
PART 1
PART 2
Shining a Light on the Clinical Data
Supporting the Use of Adjuvant,
Neoadjuvant, and Perioperative
Immunotherapy in Resectable NSCLC
PeerView.com/AWU827
Closer to a Cure or Added Clinical
Complexity? Making Sense of the
Innovations for Immunotherapy in
Resectable NSCLC
Resectable L Cancer: Poor Prognosis‘
5-y OS»
= Stage IB: 71%
Stage IIA: 64%
Stage IIB: 55%
~~ Stage IIIA: 37%
0 6 12 18 24 30 36 42 48 54 60 66 72
Time, mo
Agrón 1 tx Eston of TAM Staging of Lng Cancer.
Y Chant Ket J Thorac Oncol 201.12:108-1121 PeerView
PeerView.com/AWU827 Copyright © 2000-2024, Peerview
5-y OS»
= Stage IB: 71%
Stage IIA: 64%
Stage IIB: 55%
~~ Stage IIIA: 37%
0 6 12 18 24 30 36 42 48 54 60 66 72
Time, mo
Agrón 1 tx Eston of TAM Staging of Lng Cancer.
Y Chant Ket J Thorac Oncol 201.12:108-1121 PeerView
PeerView.com/AWU827 Copyright © 2000-2024, Peerview
rative Therapy fo cally Advanced NSC.
For locoregional
control x
Surgery \ .
cy Radiation therapy (
a To reduce risk CEE
Systemic therapy of distant relapse
Chemotherapy
Targeted therapy
Immunotherapy
PeerView
PeerView.com/AWU827 Copyright © 2000-2024, PeerView
For locoregional
control x
Surgery \ .
cy Radiation therapy (
a To reduce risk CEE
Systemic therapy of distant relapse
Chemotherapy
Targeted therapy
Immunotherapy
PeerView
PeerView.com/AWU827 Copyright © 2000-2024, PeerView
The Evolving operative Immunotherapy Landscape
Adjuvant Neoadjuvant Perioperative
IMpower010 CheckMate -816 KEYNOTE-671
PEARLS/KEYNOTE-091
BR.31?
AEGEAN
Neotorch
CheckMate -77T
RATIONALE-315
ANVIL IMpower030
ALCHEMIST chemo-1O
MERMAID
‘eponod dts snc ho na proa PeerView
PeerView.com/AWU827 Copyright © 2000-2024, PeerView
Adjuvant Neoadjuvant Perioperative
IMpower010 CheckMate -816 KEYNOTE-671
PEARLS/KEYNOTE-091
BR.31?
AEGEAN
Neotorch
CheckMate -77T
RATIONALE-315
ANVIL IMpower030
ALCHEMIST chemo-1O
MERMAID
‘eponod dts snc ho na proa PeerView
PeerView.com/AWU827 Copyright © 2000-2024, PeerView
Overview of Key Immunotherapy Strategies and Trials
Teal 10 KEYNOTE.091 BREI ChockMat AEGEAN — Neotorch KEYNOTE-S71 CheckMato-77T RATIONALE-315
Timing Aduvent Aduvant Adjuvant Neoeduvant Periperaive Perioperative Perioperative Perioperative Perioperative
Size 1.005 147714154477) 358 802 500 797 as 459
agent Aezoizumab Pembrolzumab Dunalımab Niokmab Durvalımab Torpalmab Pembrakzumab Nvaumab Tilsizumab
= (PD-L1) (ro) (PO-L1) (PD-1) (PO-L1) (PD-1) (PD-1) (PD-1) (PD-1)
Cycles, N 16 18 12 3 16 7 8 6 2
Completely Completely CPE Resocable Reseciabie Fe
ns Tesociod resected RER 18 EMB Resectablo.— Resectable. #324100 Rosca A
ehem Bram CSM Crema by mus) un A an)
(th) en) fut an) lobectomy
Stage Hi, % 59/41 72/28 zu 36/64 2/71 20180 sm 35165 41/59
DFS,
Primary DFS DFS,DFS 2
5 POLI225%.4 pCREFS pCREFS MPREFS EFS,0S ers EFS, MPR
endpoint hierarchical inPO-Li 250% ED aca
splat Dro ae inum latinum isplatin latinum latinum
a Ge QE, uam Met a ed al dit ub
encouraged eligible m ds ”
Nodocumented No No EGFR
EGFRALK Included (15%) Included (7.43%) — Included mutation, WT! documented WT Includad(7%) no documented WT
Asia mutation AK
PeerView
PeerView.com/AWU827
Copyright © 2000-2024, PeerView
Teal 10 KEYNOTE.091 BREI ChockMat AEGEAN — Neotorch KEYNOTE-S71 CheckMato-77T RATIONALE-315
Timing Aduvent Aduvant Adjuvant Neoeduvant Periperaive Perioperative Perioperative Perioperative Perioperative
Size 1.005 147714154477) 358 802 500 797 as 459
agent Aezoizumab Pembrolzumab Dunalımab Niokmab Durvalımab Torpalmab Pembrakzumab Nvaumab Tilsizumab
= (PD-L1) (ro) (PO-L1) (PD-1) (PO-L1) (PD-1) (PD-1) (PD-1) (PD-1)
Cycles, N 16 18 12 3 16 7 8 6 2
Completely Completely CPE Resocable Reseciabie Fe
ns Tesociod resected RER 18 EMB Resectablo.— Resectable. #324100 Rosca A
ehem Bram CSM Crema by mus) un A an)
(th) en) fut an) lobectomy
Stage Hi, % 59/41 72/28 zu 36/64 2/71 20180 sm 35165 41/59
DFS,
Primary DFS DFS,DFS 2
5 POLI225%.4 pCREFS pCREFS MPREFS EFS,0S ers EFS, MPR
endpoint hierarchical inPO-Li 250% ED aca
splat Dro ae inum latinum isplatin latinum latinum
a Ge QE, uam Met a ed al dit ub
encouraged eligible m ds ”
Nodocumented No No EGFR
EGFRALK Included (15%) Included (7.43%) — Included mutation, WT! documented WT Includad(7%) no documented WT
Asia mutation AK
PeerView
PeerView.com/AWU827
Copyright © 2000-2024, PeerView
tanding Evidence: Treatment Length and Median
p in Months in Selected Immunotherapy Trials
HA Treatment length
Median follow-up
IMpower010!
KEYNOTE-091?
CheckMate -816°
AEGEAN!
Neotorch®
KEYNOTE-671°
CheckMate -77T7
0 6 12 18 24 30 36 42 48 54 60 66 72
1. Wakeloo Het al ASCO 2024, Abstract LBAB035 2 Besse B at al. Ann Oncol. 2023:20{suppl 1):100880. 3. Spicar JO at al, ASCO 2024. Abstract LBABOYO.
À Heymach Net WCLE 202. Anaract OA 6. Lu Sata ASCO 2023. Ans 8016, Sper JO a Lancet 2024 404(10439/1240-1282 r
7. Spicer Det al ESMO 2024 Abstract LBASO. PeerView
PeerView.com/AWU827 Copyright © 2000-2024, PeerView
p in Months in Selected Immunotherapy Trials
HA Treatment length
Median follow-up
IMpower010!
KEYNOTE-091?
CheckMate -816°
AEGEAN!
Neotorch®
KEYNOTE-671°
CheckMate -77T7
0 6 12 18 24 30 36 42 48 54 60 66 72
1. Wakeloo Het al ASCO 2024, Abstract LBAB035 2 Besse B at al. Ann Oncol. 2023:20{suppl 1):100880. 3. Spicar JO at al, ASCO 2024. Abstract LBABOYO.
À Heymach Net WCLE 202. Anaract OA 6. Lu Sata ASCO 2023. Ans 8016, Sper JO a Lancet 2024 404(10439/1240-1282 r
7. Spicer Det al ESMO 2024 Abstract LBASO. PeerView
PeerView.com/AWU827 Copyright © 2000-2024, PeerView
g Evidence: Pathologic Response
Pathologic Complete Response (pCR)
3 cycles Up to 4 cycles
60
50
= 40
go 24 258
e 20 172 18.1
LE mm om 1
0
Forde Pet a Eng Med 2022506 97108, 2 mach et AAGR 2023 Abstract TOOS 3 ak ei. Engl Med, 2023 8849.05
al ESMO 202 PeerView
PeerView.com/AWU827 Copyright © 2000-2024, PeerView
Pathologic Complete Response (pCR)
3 cycles Up to 4 cycles
60
50
= 40
go 24 258
e 20 172 18.1
LE mm om 1
0
Forde Pet a Eng Med 2022506 97108, 2 mach et AAGR 2023 Abstract TOOS 3 ak ei. Engl Med, 2023 8849.05
al ESMO 202 PeerView
PeerView.com/AWU827 Copyright © 2000-2024, PeerView
Understanding Evidence: DFS/EFS Results!72
ños Adjuvant Neoadjuvant Perioperative
90
y 0 HR=07 HR=81 HR=0.66 HR=0.69 HR = 0.40 HR= 059 HR = 0.59
= 70 667 65
{rd 60.1
u 6071 532 524 “ ee 54
a
@ 50 oF 4 6.1 pri
S % 38 35
30
20
10
o
IMpower010 KEYNOTE-091 CheckMate -816 AEGEAN Neotorch— KEYNOTE-671 CheckMate -77T
Please noe tat he cammenar references 2-yar aa, but is sio onger
Vitae ket a ASCO 2020 Above BARES 2 Bosse el EMI Immun Only Congress 2058, Absrac 1200.
3 Spica Jet al ASCO 2024, Abtrac1 801.4. Hoymach JV a al WCLC 2024. AbsvactOA12.02. 5 Lu S atl ASCO 2023. Abstract 8601 A
6. Spicer JD tal Lance. 20240010459) 1240-1252. 7. Spice JD et al ESMO 2024, Abstract ASD PeerView
PeerView.com/AWU827 Copyright © 2000-2024, PeerView
ños Adjuvant Neoadjuvant Perioperative
90
y 0 HR=07 HR=81 HR=0.66 HR=0.69 HR = 0.40 HR= 059 HR = 0.59
= 70 667 65
{rd 60.1
u 6071 532 524 “ ee 54
a
@ 50 oF 4 6.1 pri
S % 38 35
30
20
10
o
IMpower010 KEYNOTE-091 CheckMate -816 AEGEAN Neotorch— KEYNOTE-671 CheckMate -77T
Please noe tat he cammenar references 2-yar aa, but is sio onger
Vitae ket a ASCO 2020 Above BARES 2 Bosse el EMI Immun Only Congress 2058, Absrac 1200.
3 Spica Jet al ASCO 2024, Abtrac1 801.4. Hoymach JV a al WCLC 2024. AbsvactOA12.02. 5 Lu S atl ASCO 2023. Abstract 8601 A
6. Spicer JD tal Lance. 20240010459) 1240-1252. 7. Spice JD et al ESMO 2024, Abstract ASD PeerView
PeerView.com/AWU827 Copyright © 2000-2024, PeerView
Und
tanding Evidence: OS Results!
100 Adjuvant> Neoadjuvant Perioperative
HR=071 HR=072
90 HR = 0.77 (98.36 C1%: 0.47-1.07) (95% CI: 0.56-0.93)
(65% CI: 0.56-1.06) P=.045 P= 005
80 748 a di
70 66.3 mn
2 60 58
uy 50
S 40
30
20
10
0
IMpower010 CheckMate -816 KEYNOTE-671
aio An ett ASCO 020 ot BASSES, 2, Spice a ASCO BURL, Alıa COTO 3 Spor JO Gl Lone, 2028 ADAIDABO) 240-262, PeerView
PeerView.com/AWU827 Copyright © 2000-2024, PeerView
tanding Evidence: OS Results!
100 Adjuvant> Neoadjuvant Perioperative
HR=071 HR=072
90 HR = 0.77 (98.36 C1%: 0.47-1.07) (95% CI: 0.56-0.93)
(65% CI: 0.56-1.06) P=.045 P= 005
80 748 a di
70 66.3 mn
2 60 58
uy 50
S 40
30
20
10
0
IMpower010 CheckMate -816 KEYNOTE-671
aio An ett ASCO 020 ot BASSES, 2, Spice a ASCO BURL, Alıa COTO 3 Spor JO Gl Lone, 2028 ADAIDABO) 240-262, PeerView
PeerView.com/AWU827 Copyright © 2000-2024, PeerView
Resolving Controversies
Neoadjuvant/Perioperative Chemo-IO by Stage?!
Stage 11
Forde 2022% Stage Il 65 se =
Wakalee 2023 Stage ll 118 121 =
Heymach 2023 Stage Il 104 110 nn 0.76 10.43: 1.34]
Cascone 2023 Stage 11 sr oe 081 10.46: 1.43]
Random effects model ara - 0.71 0.35;0:92]
Heterogencity: 1 = 0%, = < 01, p =0.68
Stage i
Forde 2022 Stage I 1 ns — 0.54 (0.37:0.80]
Welle 20238 Stage It 217 224 = 057 [0.44 0.74]
Viakoloo 20230 Stage Il 62 ss —— 0.57 (0.36:0.90]
Hoymach 20238 Stage ll 173 165 o 0.57 (0.99; 0.83]
Hoymach 20239 Stage ll #8 98 ce 083 (0.52: 1.32]
Provencio 2023 Stage Il El 2 —— 0.47 (0.26; 0.88]
Lu 2029 Stage Il 202 202 Eu 039 [0.27: 0.57]
Cascone 2023 Stage It 146 149 ES 051 (0.36; 0.72]
Random effects model 1058 1097 . 0.54 (0.48; 0.62)
Hoterogonoity: I? = 0%, 7 =<0.1, p 20.47
tT
o2 os 1 2 5
Favors Chemo:0. Fevers Chemo
1. Sorin tal JAMA Oncol 2028:10:621-59, PeerView
PeerView.com/AWU827 Copyright © 2000-2024, Peerview
Neoadjuvant/Perioperative Chemo-IO by Stage?!
Stage 11
Forde 2022% Stage Il 65 se =
Wakalee 2023 Stage ll 118 121 =
Heymach 2023 Stage Il 104 110 nn 0.76 10.43: 1.34]
Cascone 2023 Stage 11 sr oe 081 10.46: 1.43]
Random effects model ara - 0.71 0.35;0:92]
Heterogencity: 1 = 0%, = < 01, p =0.68
Stage i
Forde 2022 Stage I 1 ns — 0.54 (0.37:0.80]
Welle 20238 Stage It 217 224 = 057 [0.44 0.74]
Viakoloo 20230 Stage Il 62 ss —— 0.57 (0.36:0.90]
Hoymach 20238 Stage ll 173 165 o 0.57 (0.99; 0.83]
Hoymach 20239 Stage ll #8 98 ce 083 (0.52: 1.32]
Provencio 2023 Stage Il El 2 —— 0.47 (0.26; 0.88]
Lu 2029 Stage Il 202 202 Eu 039 [0.27: 0.57]
Cascone 2023 Stage It 146 149 ES 051 (0.36; 0.72]
Random effects model 1058 1097 . 0.54 (0.48; 0.62)
Hoterogonoity: I? = 0%, 7 =<0.1, p 20.47
tT
o2 os 1 2 5
Favors Chemo:0. Fevers Chemo
1. Sorin tal JAMA Oncol 2028:10:621-59, PeerView
PeerView.com/AWU827 Copyright © 2000-2024, Peerview
Resolving Controversies:
Neoadjuvant/Perioperative Chemo-IO for OS?!
All patients
Forde 2022 All patients
Wakelee 2023 Allpatients
Provencio 2023 All patients
Lu 2023 Alpatients
Random effects model
Heterogeneiy: = 0%, Y = <0.1, p = 057
1. Sonn et al. JAMA Oncol. 2024:10:621-639,
PeerView.com/AWU827
179
397
57
179
400
29
202
810
02
let
0.5
1
0.57 (0.38; 0.87]
0.72 (0.56: 0.93]
ATA
2 5
Favors Chemo-IO Favors Chemo
PeerView
Copyright © 2000-2024, Peerview
Neoadjuvant/Perioperative Chemo-IO for OS?!
All patients
Forde 2022 All patients
Wakelee 2023 Allpatients
Provencio 2023 All patients
Lu 2023 Alpatients
Random effects model
Heterogeneiy: = 0%, Y = <0.1, p = 057
1. Sonn et al. JAMA Oncol. 2024:10:621-639,
PeerView.com/AWU827
179
397
57
179
400
29
202
810
02
let
0.5
1
0.57 (0.38; 0.87]
0.72 (0.56: 0.93]
ATA
2 5
Favors Chemo-IO Favors Chemo
PeerView
Copyright © 2000-2024, Peerview
Resolving Controversies
Neoadjuvant/Perioperative Chemo-IO by PD-L1?1
1. Sorin tal. JAMA Oncol. 2026:10:621-633,
PeerView.com/AWU827
Pou cin
Forde 2022
Waive 2023
Heynach 2029
2008
Cascone 2028
Random electa model
Hatooeraty 0% 701, 2091
Pou 140%
Mae 2029,
Hormach 2023
lw 20%
Carcone 2023
Random ects model
Here at 3% Pe apa
POUI 250%
Forde 2022.
iwi 2023
Meymac 2028,
tu 2028
Ccascone 2020
Random eects model
Mena 32% P= «01, p02
Pour <i
Pou ais
pots ats,
POL etm,
pou etm,
Pots 140%
PO: 140%
PO: 140%
POL 149%
POL: 140%
POL: mo
POL: or
POL: 250%
POL: o
POL: aso
7
138
m
sr
wr
195
»
132
45
a
181
125
sie
$
m
52
= 004 lost: 1.321
975 1058: 1011
076 Bm
089 1033:1 001
073 1047: 1.161
074 (0.82;0.89)
a”
o
= 0.98 10301121
- (082 130:079]
= 070 10.49; 1.05)
—— 031 10.18.05]
a. 076 1o46:1 251
- 056 naar
=
|
025 R.10:0011
‘048 1033:0.71]
060 1035: 1011
031 (15:06,
. 026 10:12:05]
- 040 [0.20:0.56)
Feerview
Copyright © 2000-2024, PeerView
Neoadjuvant/Perioperative Chemo-IO by PD-L1?1
1. Sorin tal. JAMA Oncol. 2026:10:621-633,
PeerView.com/AWU827
Pou cin
Forde 2022
Waive 2023
Heynach 2029
2008
Cascone 2028
Random electa model
Hatooeraty 0% 701, 2091
Pou 140%
Mae 2029,
Hormach 2023
lw 20%
Carcone 2023
Random ects model
Here at 3% Pe apa
POUI 250%
Forde 2022.
iwi 2023
Meymac 2028,
tu 2028
Ccascone 2020
Random eects model
Mena 32% P= «01, p02
Pour <i
Pou ais
pots ats,
POL etm,
pou etm,
Pots 140%
PO: 140%
PO: 140%
POL 149%
POL: 140%
POL: mo
POL: or
POL: 250%
POL: o
POL: aso
7
138
m
sr
wr
195
»
132
45
a
181
125
sie
$
m
52
= 004 lost: 1.321
975 1058: 1011
076 Bm
089 1033:1 001
073 1047: 1.161
074 (0.82;0.89)
a”
o
= 0.98 10301121
- (082 130:079]
= 070 10.49; 1.05)
—— 031 10.18.05]
a. 076 1o46:1 251
- 056 naar
=
|
025 R.10:0011
‘048 1033:0.71]
060 1035: 1011
031 (15:06,
. 026 10:12:05]
- 040 [0.20:0.56)
Feerview
Copyright © 2000-2024, PeerView
g Immunotherapy Into Treatment Plans in Resectable
What We Need to Know and Do
a Select appropriate patients
e Determine sequence of therapies
© Appropriate pre- and intraoperative nodal staging
© Understand the evidence
© Plan for potential technical challenges
PeerView
PeerView.com/AWU827 Copyright © 2000-2024, PeerView
What We Need to Know and Do
a Select appropriate patients
e Determine sequence of therapies
© Appropriate pre- and intraoperative nodal staging
© Understand the evidence
© Plan for potential technical challenges
PeerView
PeerView.com/AWU827 Copyright © 2000-2024, PeerView
Patient Selection Considerations
Staging
Physiologic Evaluation
Biomarker testing
CT
PET PFTs
EBUS/med Cardiac eval
Brain MRI Exercise testing
Frailty assessment
PeerView
PeerView.com/AWU827 Copyright © 2000-2024, PeerView
Staging
Physiologic Evaluation
Biomarker testing
CT
PET PFTs
EBUS/med Cardiac eval
Brain MRI Exercise testing
Frailty assessment
PeerView
PeerView.com/AWU827 Copyright © 2000-2024, PeerView
FABLE NSCLC | OUTLINE
PART 1
PART 2
Shining a Light on the Clinical Data
Supporting the Use of Adjuvant,
Neoadjuvant, and Perioperative
Immunotherapy in Resectable NSCLC
Closer to a Cure or Added Clinical
Complexity? Making Sense of the
Innovations for Immunotherapy in
Resectable NSCLC
Copyright © 2000-2024, PeerView
PART 1
PART 2
Shining a Light on the Clinical Data
Supporting the Use of Adjuvant,
Neoadjuvant, and Perioperative
Immunotherapy in Resectable NSCLC
Closer to a Cure or Added Clinical
Complexity? Making Sense of the
Innovations for Immunotherapy in
Resectable NSCLC
Copyright © 2000-2024, PeerView
hallenging Clinical Questions
PeerView
PeerView.com/AWU827 Copyright © 2000-2024, PeerView
PeerView
PeerView.com/AWU827 Copyright © 2000-2024, PeerView
Challenging Clinical Questions
How do we decide between
neoadjuvant, adjuvant, and perioperative strategies?
PeerView
Copyright © 2000-2024, PeerView
How do we decide between
neoadjuvant, adjuvant, and perioperative strategies?
PeerView
Copyright © 2000-2024, PeerView
Challenging Clinical Questions
Is there a preferred platinum-based chemotherapy agent
that should be used as part of perioperative therapy?
PeerView
Copyright © 2000-2024, PeerView
Is there a preferred platinum-based chemotherapy agent
that should be used as part of perioperative therapy?
PeerView
Copyright © 2000-2024, PeerView
allenging Clinical Questions
How can we balance improved clinical efficacy while
avoiding overtreatment and increased toxicity?
PeerView
Copyright © 2000-2024, PeerView
How can we balance improved clinical efficacy while
avoiding overtreatment and increased toxicity?
PeerView
Copyright © 2000-2024, PeerView
PeerView
PeerView.com/AWU827 Copyright © 2000-2024, PeerView
PeerView.com/AWU827 Copyright © 2000-2024, PeerView
PeerView
PeerView.com/AWU827 Copyright © 2000-2024, PeerView
PeerView.com/AWU827 Copyright © 2000-2024, PeerView
Challenging Clinical Questions
| Is there an optimum or minimum treatment duration in the
| adjuvant setting that we should utilise?
PeerView
Copyright © 2000-2024, PeerView
| Is there an optimum or minimum treatment duration in the
| adjuvant setting that we should utilise?
PeerView
Copyright © 2000-2024, PeerView
Challenging Clinical Questions
How does utilising perioperative immunotherapy approaches
impact long-term management of patients?
PeerView
Copyright © 2000-2024, PeerView
How does utilising perioperative immunotherapy approaches
impact long-term management of patients?
PeerView
Copyright © 2000-2024, PeerView
Conclusions & Key Takeaways
Download
Download Slideshow Get the original presentation fileQuick Actions
Statistics
- Views 166
- Slides 26
- Age 426 days
Related Slideshows
36
Clinical approach Dyspnoea A simple and practical approach.pptx
ShajahanPS
37 views
238
Cancer Awareness therapy for public by Dr Kanhu Charan Patro
kanhucpatro
37 views
41
Prof Satyadas Memorial oration Kozhikode.pptx
ShajahanPS
33 views
26
Viral Conjunctivitis and it;s managment.pptx
ZaidAzhar
45 views
30
Essential Thrombocythemia 15 Years of Experience at the Hematology Department, Algies, Algeria.pdf
sbelakehal
40 views
10
Hypertension sign symptoms cmdt style with regime
androiddabest
41 views